Kanpur: Sisamau Super Kings emerged as champions of the first Kanpur Premier League, defeating strong contender Mayur ...

The deal, which is expected to be in the range of ₹100 crore, will enable SRF to expand and complement its existing offerings ...

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA) plans to discontinue development of its drug abiprubart for the treatment of Sjögren’s ...

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical ...

Kanpur: Awanish Awasthi, chief advisor to the chief minister Yogi Adityanath, will unveil the KPL trophy in a grand function scheduled to be held here.

Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing ...

Reports Q4 revenue $122.5M, consensus $123.38M. “Strong commercial execution in 2024 resulted in 79% year-over-year ARCALYST sales growth to ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and ...

Darajani Gogo FC held a successful fundraiser, securing crucial funds for team operations and community initiatives.